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ABSTRACT
Background: Environmental enteropathy (EE) refers to villus
blunting, reduced absorption, and microbial translocation in children
and adults in tropical or deprived residential areas. In previous work
we observed an effect of micronutrients on villus height (VH).
Objective:We aimed to determine, in a randomized controlled trial,
if amino acid (AA) or multiple micronutrient (MM) supplementation
can improve intestinal structure or barrier dysfunction in Zambian
adults with EE.
Methods: AA (tryptophan, leucine, and glutamine) and/or MM
supplements were given for 16 wk in a 2 × 2 factorial comparison
against placebo. Primary outcomes were changes in VH, in vivo
small intestinal barrier dysfunction assessed by confocal laser
endomicroscopy (CLE), and mechanistic (or mammalian) target of
rapamycin complex 1 (MTORC1) nutrient responsiveness in lamina
propria CD4+ lymphocytes.
Results: Over 16 wk AA, but not MM, supplementation increased
VH by 16% (34.5 μm) compared with placebo (P = 0.04). Fluo-
rescein leak, measured by CLE, improved only in those allocated to
both AA andMM supplementation. No effect was seen onMTORC1
activation, but posttreatment MTORC1 and VH were correlated
(ρ = 0.51; P = 0.001), and change in MTORC1 was correlated
with change in VH in the placebo group (ρ = 0.63; P = 0.03).
In secondary analyses no effect was observed on biomarkers of
microbial translocation. Metabolomic analyses suggest alterations
in a number of microbial- and host-derived metabolites including
the leucine metabolite β-hydroxy-β-methylbutyrate, which was
increased by AA supplementation and correlated with VH.
Conclusions: In this phase 2 trial, AA supplementation protected
against a decline in VH over the supplementation period, and
improved barrier function when combined with micronutrients.
Leucine and MTORC1 metabolism may be involved in the
mechanism of effect. This trial was registered at www.pactr.org as
PACTR201505001104412. Am J Clin Nutr 2019;00:1–13.
Keywords: environmental enteropathy, amino acids, micronutri-
ents, MTOR, confocal endomicroscopy, morphometry, clinical trial,
metabolomics, Zambia
Introduction
Environmental enteropathy (EE) was first recognized as
“tropical enteropathy,” a phenomenon of uncertain significance
(1–3). There is now evidence that it underlies the growth
impairment of millions of young people globally (4, 5), impairs
Supported by CORE, UK (to JL-A) and Bill & Melinda Gates Foundation
grant OPP1066118 (to PK). The micronutrient supplement and matching
placebo were generously manufactured and donated by Vitabiotics Ltd, UK.
Supplemental Tables 1–6, Supplemental Figures 1–3, and Supplemental
Methods are available from the “Supplementary data” link in the online
posting of the article and from the same link in the online table of contents at
https://academic.oup.com/ajcn/.
Data described in the article (an anonymized database) will be made
available upon request to the corresponding author pending application and
approval.
Address correspondence to PK (e-mail: m.p.kelly@qmul.ac.uk).
Abbreviations used: AA, amino acid; CLE, confocal laser endomicroscopy;
CRP, C-reactive protein; EE, environmental enteropathy; GLP-2, glucagon-
like peptide 2; HMB, β-hydroxy-β-methylbutyrate; IDO, indoleamine 2,3-
dioxygenase; KTR, kynurenine to tryptophan ratio; MFI, mean fluorescence
intensity; MM, multiple micronutrient; MTORC1, mechanistic (or mam-
malian) target of rapamycin complex 1; MUAC, midupper arm circum-
ference; NMNA, N-methylnicotinic acid; NMND, N-methylnicotinamide;
OPLS, orthogonal projection to latent structures; p4E-BP1, phospho-4E-
binding protein 1; PAG, phenylacetylglutamine; sCD14, soluble CD14; VH,
villus height; 2-PY, N-methyl-2-pyridone-5-carboxamide.
Received May 3, 2019. Accepted for publication July 18, 2019.
First published online 0, 2019; doi: https://doi.org/10.1093/ajcn/nqz189.
Am J Clin Nutr 2019;00:1–13. Printed in USA. Copyright©American Society for Nutrition 2019. All rights reserved. This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution,
and reproduction in any medium, provided the original work is properly cited. 1
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/advance-article-abstract/doi/10.1093/ajcn/nqz189/5556068 by guest on 13 Septem
ber 2019
2 Louis-Auguste et al.
the neurocognitive development of children (6), contributes
to micronutrient deficiencies through impaired absorption of
nutrients (7), and may blunt responses to oral vaccines (5, 8).
The definitive assessment of EE requires small intestinal
biopsy (1, 9). Recent work has established that assessment of
fecal inflammatory and permeability markers can be used to
evaluate the severity of EE (10–12), and these markers correlate
with ponderal growth (12, 13). Recent metabolomic studies have
found that EE is associated with perturbations in choline and
tryptophan metabolism (14, 15). Transcriptomic analysis of stool
RNA has shown that transcripts related to cell adhesion and
to responses to viral and other pathogens characterize EE (16).
We have recently reported that confocal endomicroscopy can be
used to quantify leakiness of the epithelium in EE (17). T cell–
mediated inflammation is a feature of EE, but the drivers of the
mucosal immune response are as yet unknown.
There are currently no established therapies for EE, and
even preventive strategies have been unsuccessful to date. Water
and sanitation trials have so far proved disappointing (18, 19).
Antibiosis using rifaximin did not alter lactulose permeation
in Malawian children (20). There is divergent evidence on the
effects of antihelminthics (21, 22). Probiotics were ineffective
(23), as was anti-inflammatory therapy using mesalazine (24).
New treatments are needed (25). We previously reported
preliminary evidence that micronutrient supplementation could
improve villus morphology (26). There are data which suggest
that glutamine can reduce intestinal permeability (27, 28), but
there are also negative trial data (29). In view of this preliminary
evidence, and evidence that tryptophan metabolism is perturbed
in EE (14, 30, 31), we hypothesized that micronutrient supple-
mentation and/or supplementation with glutamine, tryptophan,
and leucine can ameliorate the mucosal pathology of EE through
modification of immune cell nutrient-sensing systems such as
mechanistic (or mammalian) target of rapamycin complex 1
(MTORC1). Here we report the results of that randomized
controlled trial.
Methods
Participants and recruitment
Participants were recruited from Misisi, Lusaka, where we
have previously conducted studies of EE (9, 17). Recruitment
followed a 3-stage process, beginning with door-to-door invita-
tions, followed by a series of focus group discussions, and then
individual interviews before written informed consent. At the
initial assessment, inclusion and exclusion criteria were assessed,
a medical and social history questionnaire was administered,
and a physical examination was carried out. A stool sample
was provided to exclude helminths and protozoal infection. An
HIV test (Determine, Abbott Diagnostics) was administered,
with a confirmatory test (Unigold, Trinity Biotech) administered
in positive cases. On the day of endoscopy, a blood sample
was collected, and body composition assessment was performed
using impedance and plethysmography (see below).
Inclusion and exclusion criteria
Participants were eligible for recruitment if between 18 and
60 y of age; male or female; resident in B section, Misisi
compound, Lusaka; and able to give informed consent. Exclusion
criteria were pregnancy (by self-report), breastfeeding (by self-
report), BMI <18 kg/m2, any antibiotic use within the previous
4 wk, regular non-steroidal anti-inflammatory drug use within
the previous 4 wk, diarrhea within the previous 4 wk, significant
comorbidity precluding endoscopy with sedation, therapeutic
anticoagulation or bleeding diathesis precluding endoscopic
biopsies, or lack of consent for HIV testing. Untreated helminth
or protozoal infection, or helminth or protozoal infection
treated within 6 mo, were also exclusion criteria; however,
participants with nonpathogenic parasites were eligible (detailed
in Supplemental Table 1).
Trial design
The trial was designed as a parallel-group phase 2 trial in which
multiple micronutrient (MM) or amino acid (AA) supplements
were compared with respective matching placebos in a 2 × 2
factorial design. The study was powered for primary outcomes
in HIV-negative individuals, although HIV-positive participants
were also included so as to avoid discrimination in this close-
knit community. We did not detect any effect of HIV status on
any of the outcomes measured, and results are reported here
combined, without reference to HIV status unless otherwise
stated.
Randomization
Each AA or matched placebo sachet and each MM or matched
placebo pillbox was labeled with 1 of 4 letters (A, B, C,
D for AA/placebo) or numbers (1, 2, 3, 4 for MM/placebo),
respectively. Two numbers and 2 letters were randomly assigned
by the manufacturer to the active supplements, with the other 2
representing the placebos. The supplements were then labeled
accordingly, and the allocation code was supplied to the
study statistician. The code was known to the manufacturer
and to the study statistician and was only revealed to the
investigators once the databases had been locked at the end of
the trial.
After completing enrollment and baseline assessments, par-
ticipants were randomly allocated in blocks of 16 by the study
statistician to 1 of the 16 possible groups (4 possible AA allo-
cations × 4 possible MM allocations) using the randomization
algorithms available at www.randomization.com (accessed 9
October, 2015 by DM). Participants were therefore allocated to
each of the 4 study arms in a 1:1:1:1 ratio.
Interventions
The MM supplement (Immunace Original) and matched
placebo were both manufactured by Vitabiotics Ltd. The AA
supplement (29.9 g l-Gln, 2.79 g l-Leu, and 0.28 g l-Trp)
and isocaloric taste-matched placebo were both manufactured
by Glanbia Nutritionals Deutschland GmbH. Both were given
daily for 16 wk (112 d). Participants were advised to take both
supplements with their main meal every day, at any time of day,
starting the day after the baseline endoscopy. The composition
and presentation of the active supplements andmatching placebos
are given in Tables 1 and 2.
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TABLE 1 Composition of the micronutrient supplement1
Average dose per
tablet
Total daily
dose EC RDA
Multiples of EC RDA
per daily dose
Vitamin A RE, IU/μg 2664/800 5328/1600 800 2
Vitamin D3, IU/μg 400/10 800/20 5 4
Vitamin E α-TE, mg 40 80 12 6.66
Vitamin K, μg 70 140 75 1.86
Vitamin C, mg 150 300 80 3.76
Thiamin, mg 18 36 1.1 32.72
Riboflavin, mg 6 12 1.4 8.58
Niacin NE, mg 27 54 16 3.38
Vitamin B-6, mg 10 20 1.4 14.28
Folic acid, μg 400 800 200 4
Vitamin B-12, μg 14 28 2.5 11.2
Pantothenic acid, mg 20 40 6 6.66
Iron, mg 8 16 14 1.14
Magnesium, mg 60 120 375 0.32
Zinc, mg 15 30 10 3
Iodine, μg 200 400 150 2.66
Copper, μg 500 1000 1000 1
Manganese, mg 4 8 2 4
Selenium, μg 180 360 55 6.54
Chromium, μg 100 200 40 5
l-Cystine, mg 40 80 N/A N/A
l-Carnitine, mg 30 60 N/A N/A
Citrus bioflavonoids, mg 30 60 N/A N/A
β-Carotene (natural carotenoids), mg 3 6 N/A N/A
1The total daily dose consisted of 2 tablets. The multiple micronutrient supplement included the following excipients: microcrystalline cellulose,
hydroxypropylmethylcellulose, ethyl cellulose, propylene glycol, purified talc, titanium dioxide, iron oxides, glucose syrup, magnesium stearate, silicon
dioxide, polyvinylpolypyrrolidone, acacia, sucrose, starch, tricalcium phosphate, dicalcium phosphate, medium-chain triglycerides, colloidal silica,
maltodextrin, and butylated hydroxyanisole. The micronutrient placebo contained only these excipients. EC RDA, European Community RDA; IU,
international units; N/A, not available; NE, niacin equivalents; RE, retinol equivalents; α-TE, α-tocopherol equivalents.
Primary endpoints
Three primary endpoints were evaluated in this phase 2 trial: 1)
change in villus height (VH)measuredmorphometrically in distal
duodenal biopsies collected during endoscopy under sedation;
2) change in in vivo small intestinal barrier leak by measuring
fluorescein leak via confocal laser endomicroscopy (CLE); and
3) change in distal duodenal lamina propria mucosal CD4+ T cell
MTORC1 activity, measured by flow cytometry.
Morphometry.
Endoscopic biopsies from distal duodenum were orientated
under a dissecting microscope at the time of endoscopy before
being fixed in formalin. Hematoxylin and eosin stained sections
of paraffin-embedded tissue were then digitally imaged using
TABLE 2 Composition of the amino acid supplement1
Active Placebo
l-Gln 29.9 g —
l-Trp 0.28 g —
l-Leu 2.79 g —
Maltodextrin — 32.9 g
Sodium hydrogen sulfite (E222) — 0.07 g
Total daily dose 33 g 33 g
1Sodium hydrogen sulfite was included as a bitterant in the placebo to
approximate the slight bitterness of tryptophan.
a Hamamatsu digital slide scanner (Hamamatsu Photonics
UK Ltd.). After identification of the villus–crypt boundary
and mucosal length by the user, several parameters were
measured: VH, villus width, crypt depth, villus perimeter per
unit length of mucosa (as a measure of 3-dimensional villus
surface area), and villus cross-sectional area per unit length of
mucosa (as a measure of 3-dimensional villus compartment
volume) (17).
CLE.
The small intestinal barrier was imaged in vivo using
fluorescein-based CLE (Pentax) as previously described (17).
The proportion of fields demonstrating fluorescein leak into
the lumen (Figure 1) was scored by 2 independent blinded
observers, whose reports demonstrated high interobserver agree-
ment (ρ = 0.94; P < 0.001; Supplemental Figure 1).
Assessment of lamina propria CD4+ T lymphocyte MTORC1
activity.
The ability of lamina propria CD4+ lymphocytes to respond to
environmental nutrients through MTORC1 activity was assessed
by measuring levels of its phosphorylated downstream tran-
scription factor target, phosphor-4E-binding protein 1 (p4E-BP1)
(31), via flow cytometry (see the Supplemental Methods). The
percentage of CD4+ T cells responding to nutrient stimulation
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FIGURE 1 Examples of reproducible endomicroscopic signs of barrier dysfunction. Top left: intact mucosa; no leak; intervillous space is black (normal;
Watson grade I). Top right: background luminal fluorescein (functional defect; Watson grade II) with a single apoptotic cell shedding event (nonpathological).
Centre left: fluorescein plume with no mucosal defects (functional defect; Watson grade II). Center right: apical microerosion (multiple cell defect) with
background fluorescein leakage (structural defect; Watson grade III). Bottom left: multiple microerosions with multiple fluorescein plumes (structural defect;
Watson grade III). Bottom right: florid fluorescein leak within and out of the mucosa with multiple microerosions (structural defect; Watson grade III).
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was calculated in FlowJo (TreeStar), using the “starved” cells as
the control population.
Secondary endpoints
Secondary endpoints measured included change in 1)
plasma markers of microbial translocation and inflammation;
2) metabolomic profile; and 3) anthropometry and body
composition.
Plasma markers of microbial translocation and inflammation.
Serumwas stored at−80◦C for analysis of LPS concentrations
using the Limulus amoebocyte lysate assay (Associates of Cape
Cod International Inc.) according to the manufacturer’s instruc-
tions. C-reactive protein (CRP) and soluble CD14 (sCD14)
(both from R&D Systems) concentrations were measured by
ELISA according to the manufacturer’s instructions. Serum
glucagon-like peptide 2 (GLP-2; EMD Millipore Corporation)
concentrations were measured by ELISA according to the
manufacturer’s instructions.
1H NMR spectroscopy–based metabolic phenotyping.
Urine samples were collected before endoscopy into a
container with 1 mL 0.5% chlorhexidine, then stored at −80◦C
until transportation to London, United Kingdom on dry ice.
Analytical details are given in the Supplemental Methods.
Multivariate statistical approaches were used to interrogate the
complex metabolic data set. This included principal component
analysis to identify the main sources of variance in the data and
to identify outliers. Orthogonal projection to latent structures
(OPLS) discriminant analysis was performed to assess the
metabolic variation between the different treatment groups (e.g.,
placebo compared with AA). Separate OPLS models were also
constructed to illuminate metabolic variation associated with
VH and MTORC1 activation. The predictive ability (Q2Y)
of the models was calculated using a 7-fold cross-validation
approach and their validity was assessed by permutation
testing (1000 permutations; with a P value threshold of
P < 0.05).
Nutritional assessments.
Study participants had BMI, midupper arm circumference
(MUAC), and grip strength measurements taken before and after
the supplementation period. Body composition pre- and post-
supplementation was assessed using whole-body air displace-
ment plethysmography (BodPod, COSMED) and bioelectrical
impedance (Tanita Corporation).
Data analysis and statistical considerations
The study was powered to demonstrate the superiority of
MM or AA supplementation over placebo in HIV-seronegative
participants. We expected a 15% difference in morphometry
to be associated with a similar degree of change in intestinal
permeability, bacterial translocation, and metabolomic profile.
Power and sample size calculations were based on morphometric
data from 2 studies of adults with enteropathy in this population
(17, 26). Sample size calculations were powered for main
effects and assumed no negative interaction between AA and
MM supplementation. To detect a difference of 15% between
an intervention and the corresponding placebo would require
56 HIV-seronegative participants—28 participants given the
supplement and 28 given the corresponding placebo (expected
difference in VH = 30 μm; SD = 40 μm; power = 0.8; 2-
sided α = 0.05). Therefore, 14 participants per combination of
interventions was the minimum sample size. Allowing for a 20%
dropout rate and 30% HIV-seropositive rate (17), we anticipated
that 100 participants were required. Using the Shapiro–Wilk test,
measures of morphometry and biomarkers were nonnormally
distributed and are therefore reported as median [IQR]. However,
measurements of change in morphometry, fluorescein leakage,
and MTORC1 activation did not depart significantly from the
normal distribution and are reported as mean ± SD.
Clinical trial approvals
The study protocol and trial were approved by the University
of Zambia Biomedical Research Ethics Committee (reference
007-11-14, dated 22 January, 2015), the Zambia Medicines
Regulatory Authority (reference CT054/15), and the National
Health Research Authority of Zambia (29 October, 2015),
and registered with the Pan African Clinical Trials Registry
(PACTR201505001104412). A favorable nonbinding opinion
was also obtained fromQueenMary University of London Ethics
of Research Committee (ref. QMERC2014/77).
Results
The trial was carried out between October 2015 andMay 2016.
The timing of recruitment was such that treatment was initiated in
November–December 2015 (before the rainy season) and the final
measurements after treatment were made in March–April 2016
(after the rainy season). One hundred and two participants were
recruited and randomly allocated, and 85 were included in the
final analysis (Figure 2). Compliance was high (Supplemental
Figure 2).
Participant characteristics
Age, sex, nutritional status (BMI, MUAC, fat distribution, grip
strength), and other baselinemeasurements for primary endpoints
were comparable between the treatment groups (Table 3).
Primary endpoint: mucosal morphometry
Unfortunately, in several cases it was not possible for an
experienced technician to obtain well-orientated sections suitable
for morphometry, resulting in a reduction in the number of
paired samples available for analysis. Nevertheless, there was
a general reduction in villus and crypt measurements in all
groups between the first and second biopsies, which may relate
to seasonality (9). The reduction in VH and villus cross-
sectional area was significantly less in participants given AA
supplementation compared with placebo (Table 4; Figure 3).
This effect of AA supplementation on VH was confirmed in
linear regression models in whichMUAC, fat mass, grip strength,
and HIV status were included; only AA supplementation
remained a significant contributor to the model (P = 0.03;
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FIGURE 2 Consolidated Standards of Reporting Trials flow diagram of participants through the trial. Total numbers of participants are given, with the
number of HIV-positive participants in parentheses. AA, amino acid; MM, multiple micronutrient; OGD, oesophagogastroduodenoscopy; P, placebo.
Supplemental Table 2). MM supplementation had no effect on
any morphometric measurement (Table 4). HIV status had no
effect on morphometric parameters at baseline (data not shown)
and had no effect on the change in VH over the supplementation
period (mean ± SD: −28 ± 57 in HIV seropositives compared
with −8.6 ± 61 in HIV seronegatives; P = 0.30).
Primary endpoint: assessment of barrier dysfunction by
CLE
Barrier leak was assessed using CLE (Figure 1). The median
number of fields available for analysis was 72 at baseline and 98
after supplementation (IQR: 49–98 and 78–117.5, respectively).
The mean ± SD change in the percentage of fields in which
fluorescein leakage was detected was −10.1% ± 31% in the
AA group compared with −5.1% ± 36% in the placebo group
(P = 0.54). The mean ± SD change in the percentage of
fields evaluated in which fluorescein leakage was detected was
−11.3% ± 35% in the MM group compared with −4.3% ± 32%
in the placebo group (P = 0.39). However, leak was reduced
in the group allocated to AA + MM (P = 0.02 across all
groups, P = 0.004 for interaction). The percentage of fields in
which fluorescein leakage was observed was not correlated with
morphometric or nutritional measurements (data not shown).
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TABLE 3 Baseline characteristics1
AA arm MM arm
AA (n = 42) Placebo (n = 43) MM (n = 42) Placebo (n = 43)
Sex, M:F 16:26 11:32 12:30 15:28
Age, y 35 [28, 46] 42 [24, 51] 40 [21, 47] 40 [30, 46]
HIV seropositive 13 (31%) 14 (33%) 16 (38%) 11 (26%)
BMI, kg/m2 23.1 [19.9, 25.1] 22.3 [20.5, 27.7] 23.1 [20.2, 26.7] 22.0 [19.9, 25.9]
MUAC, cm 27.3 [25.4, 30.1] 28.5 [25.8, 32.0] 28.3 [25.4, 31.1] 27.9 [25.4, 31.3]
Grip strength, kg 31.8 [25.0, 39.2] 29.2 [27.1, 36.9] 30.7 [27.7, 36.1] 31.2 [25.7, 37.7]
Fat percentage, by impedance 24.1 [14.7, 30.0] 25.3 [17.6, 36.2] 25.2 [16.5, 31.6] 24.1 [15.7, 34.4]
Fat percentage, by
plethysmography
24.5 [17.3, 34.3] 30.9 [19.3, 40.6] 30.3 [17.6, 37.6] 28.5 [17.3, 36.1]
VH, μm 185 [154, 217] 218 [201, 250] 202 [181, 252] 206 [170, 235]
CD, μm 163 [141, 196] 163 [150, 198] 157 [135, 194] 174 [152, 199]
VW, μm 230 [210, 263] 222 [197, 268] 221 [202, 253] 230 [205, 267]
VP, μm, per unit mucosa 865 [702, 1030] 987 [868, 1134] 931 [788, 1072] 913 [772, 1090]
VA, μm2, per unit mucosa 30,061 [23,036, 37,178] 32,328 [27,992, 40,093] 31,998 [23,619, 37,642] 31,288 [24,892, 37,200]
Fluorescein leak, % fields 85 [66, 91] 79 [57, 89] 80 [56, 91] 86 [75, 91]
p4E-BP1 positive LP CD4+, % 48 [41, 57] 60 [45, 66] 58 [46, 65] 49 [36, 62]
LPS, EU/mL 158 [106, 257] 155 [94, 232] 173 [108, 251] 150 [89, 244]
CRP, μmol/mL 1.9 [0.6, 3.6] 3.9 [1.1, 9.0] 2.2 [0.6, 7.2] 2.7 [0.9, 8.5]
sCD14, μmol/mL 1.8 [1.4, 2.4] 1.9 [1.4, 2.3] 1.7 [1.4, 2.4] 1.9 [1.5, 2.3]
GLP-2, ng/mL 0.76 [0, 1.4] 0.92 [0.5, 1.4] 0.75 [0.5, 1.5] 0.88 [0.5, 1.4]
1Values are given as median [IQR] unless otherwise stated. Fluorescein leak was defined as Watson grade II or III defects (see Methods and Figure 1 for
further details), and scored as the percentage of unique endomicroscopic fields displaying leaks. The percentage of p4E-BP1 positive LP CD4+ represents the
proportion of LP CD4+ that responds to nutrient stimulation in vitro (see the Methods for details). AA, amino acid; CD, crypt depth; CRP, C-reactive protein;
F, female; GLP-2, glucagon-like peptide 2; LP CD4+, lamina propria CD4+ T cell; M, male; MM, multiple micronutrient; MUAC, midupper arm
circumference; p4E-BP1, phospho-4E-binding protein 1 (marker of MTORC1 activation); sCD14, soluble CD14; VA, villus cross-sectional area per 100 μm
muscularis mucosae; VH, villus height; VP, villus perimeter per 100 μm muscularis mucosae; VW, villus width.
Primary endpoint: assessment of nutrient sensing by lamina
propria CD4+ T cells using p4E-BP1 as an index of
MTORC1 activation
The ability of small intestinal lamina propria CD4+ T
lymphocytes to respond to an environmental nutrient stimulus
was assessed by flow cytometry. Both basal (starved cells)
and peak (fed cells) MTORC1 activity [mean fluorescence
intensity (MFI) of p4E-BP1+ CD4+ T lymphocytes after
90 min of nutrient deprivation or stimulation, respectively]
declined over the course of the study. Basal mean ± SD MFI
declined from 286.4 ± 84.7 presupplementation to 145.5 ± 55.7
postsupplementation (P < 0.001) but this did not differ by
treatment allocation.
The mean ± SD proportion of CD4+ T lymphocytes
that were nutrient responsive (i.e., p4E-BP1+ after nutrient
stimulation) was 51.3% ± 16.3% presupplementation. The
proportion of mucosal CD4 cells responding to the nutrient
stimulus fell after the supplementation period in all groups.
The mean ± SD change was −6.1% ± 16% in 9 participants
allocated to AA supplementation, which did not significantly
TABLE 4 Changes in primary histological endpoints1
AAs (Trp, Leu, Gln) vs. placebo MMs vs. placebo
Change in: AA (n = 26) Placebo (n = 23) P MM (n = 26) Placebo (n = 23) P
Villus height, μm 2.5 ± 59 − 32.0 ± 57 0.04 − 19.5 ± 62 − 8.6 ± 60 0.53
Crypt depth, μm − 13.3 ± 39 − 31.1 ± 45 0.15 − 25.5 ± 43 − 18.3 ± 43 0.56
Villus width, μm − 11.5 ± 60 − 13.7 ± 138 0.94 − 16.6 ± 72 − 8.9 ± 126 0.80
Villus perimeter, μm, per 100
μm muscularis mucosae
− 1.9 ± 180 − 89.5 ± 159 0.08 − 64.1 ± 137 − 24.4 ± 203 0.43
Villus area, μm2, per 100 μm
muscularis mucosae
715 ± 5632 − 3220 ± 5694 0.02 − 2469 ± 5061 50.8 ± 6494 0.14
Villus surface area:volume
ratio
− 0.0009 ± 0.0007 0.0003 ± 0.006 0.50 − 0.00004 ± 0.006 − 0.0006 ± 0.006 0.76
1Values are mean ± SD. Two-tailed independent-samples t test, with normality confirmed by the Shapiro–Wilk test. AA, amino acid; MM, multiple
micronutrient.
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FIGURE 3 Change in VH and villus cross-sectional surface area per unit length of mucosa after AA (top panels) or MM (bottom panels) supplementation
compared with placebo. Mean ± SD changes are given together with Tukey’s hinges. Two-tailed independent-samples t test, with normality confirmed by the
Shapiro–Wilk test. AA, amino acid; MM, multiple micronutrient; VH, villus height.
differ from −7.4% ± 21% in 16 participants allocated to placebo
(P = 0.86). The mean ± SD change was −9.8% ± 19% in
16 participants allocated to MM supplementation, which did
not significantly differ from −3.7% ± 20% in 14 participants
allocated to placebo (P = 0.40). The small number of paired
samples available for analysis reflects the harsh permeabilization
required for p4E-BP1 staining, which as an undesired side
effect resulted in the destruction of a variable proportion of
lymphocytes.
Although MTORC1 activation was not affected by treatment
allocation, it was strongly correlated with posttreatment VH
(ρ = 0.51; P = 0.001; Supplemental Figure 3). The change in
MTORC1MFI over the period of supplementationwas correlated
with the change in VH in the placebo group (ρ = 0.63; P= 0.03),
but not in the AA group (ρ = 0.26; P = 0.62). MTORC1
activation was not associated with sex, HIV status, fat-free mass,
grip strength, or T cell activation as assessed by human leucocyte
antigen-DR expression.
Secondary endpoint: serum biomarkers
Serum concentrations of LPS, CRP, sCD14, and plasma GLP-
2 did not differ between groups at baseline (Table 3). Changes
in serum concentrations during the trial period did not differ
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TABLE 5 Metabolomic changes in 3 active treatment groups compared with placebo1
Increased with intervention Reduced with intervention P for model
MM (n = 15) vs. placebo (n = 18) Pantothenate, HMB, PAG, 4-CS NMNA, 3-HPHPA 0.01
AA (n = 16) vs. placebo (n = 18) BAIBA, PAG, 4-CS, citrate No significant changes 0.01
MM + AA (n = 17) vs. placebo (n = 18) Pantothenate, succinate, HMB, PAG, fumarate, 2-PY No significant changes 0.01
1For details of statistical analysis see Methods. AA, amino acid; BAIBA, β-amino-isobutyric acid; HMB, β-hydroxy-β-methylbutyrate; MM, multiple
micronutrient; NMNA, N-methylnicotinc acid; PAG, phenylacetylglutamine; 2-PY, N-methyl-2-pyridone-5-carboxamide; 3-HPHPA,
3-(3-hydroxyphenyl)-3-hydroxypropionic acid; 4-CS, 4-cresyl sulfate.
in participants allocated to AA or placebo, or MM or placebo
(Supplemental Table 3).
Secondary endpoint: metabolomic analysis
Having observed the effect of AA supplementation on VH,
the metabolic phenotypes were investigated for features that
might explain this effect, or correlate with the changes observed.
Significant OPLS models were obtained for the 3 active
groups (MM, AA, and both) compared with placebo (Tables 5
and 6, Figure 4).
To explore drivers of our primary endpoints, the profiles
were correlated with posttreatment VH and posttreatment
MTORC1 activation. β-Hydroxy-β-methylbutyrate (HMB),
dimethyglycine, creatine, creatinine, guanidinoacetic acid,
taurine, N-methyl-2-pyridone-5-carboxamide (2-PY), and
formate excretion were all positively correlated with VH. With
respect to MTORC1 activation, HMB, 2-hydroxyisobutyrate,
dimethylamine, pseudouridine, and 2-PY correlated positively,
whereas 4-cresyl sulfate, hippurate, and phenylacetylglutamine
(PAG) correlated negatively (Table 7). A summary of the origins
and putative biological roles of these metabolites is given in
Supplemental Table 4.
Secondary endpoint: nutritional assessment
Random allocation to MM supplementation had no impact
on change in BMI, MUAC, fat-free mass (by impedance or
plethysmography), or grip strength over this time period. There
was also no difference in nutritional parameters by random
allocation to AA supplementation (data not shown).
Safety and adverse events
All supplements were well tolerated. The most frequent
adverse events reported were feeling hungry, cough, diarrhea,
nausea, vomiting, and dizziness. There were no serious adverse
events and no deaths occurred. Adverse experiences were not
more frequent in the AA or MM groups (Supplemental Tables
5 and 6).
Discussion
EE is a subclinical alteration in small intestinal mucosal
architecture and function, widely prevalent in the tropics and
in disadvantaged communities. Previous trials have identified
few interventions which consistently and successfully target any
of the domains of pathophysiology, but nutritional or other
interventions are needed. In this double-blinded randomized
controlled trial, on a background of a seasonal reduction in
VH and villus surface area, supplementation with AA but not
MM increased VH and surface area compared with placebo.
However, the effects on intestinal barrier function (assessed
in vivo using CLE) were very modest and only seen in the
AA + MM group. There was no effect on plasma biomarkers
of microbial translocation. The pronounced correlation between
posttreatment p4E-BP1 expression in lamina propria CD4+ cells
and VH suggests that nutrient sensing by the MTORC1 pathway
in the mucosal immune compartment plays a part in determining
villus morphology, but it is also possible that improved absorptive
capacity increases MTORC1 activation. The pathway of the
effect of AA supplementation on mucosal architecture, if not
through MTORC1, remains to be determined.
Our morphometric findings are in contrast to a secondary
analysis of 1 of our previous studies which suggested that
MM supplementation exerted a protective effect on small bowel
histology (26). We cannot offer a robust explanation for this
finding, but we speculate that seasonality may contribute to
this discrepancy because the first study was conducted during
the dry season and this study was conducted over the course
of hot and rainy seasons. We and others have consistently
demonstrated a seasonal variation in mucosal structure and/or
TABLE 6 Metabolomic changes over the supplementation period by treatment group1
Increased over time Reduced over time P for model
MM pre vs. post (n = 18) Pantothenate, HMB, succinate, 2-PY, NMND BAIBA, 4-HH, 3-IS 0.01
AA pre vs. post (n = 16) Citrate, myo-inositol, formate Taurine, glycolate, trans-aconitate 0.01
MM + AA pre vs. post (n = 16) Pantothenate, HMB, succinate, 2-PY, PAG,
citrate, NMND, unknown
BAIBA, 2-HIB, choline, acetylcholine,
taurine, hippurate
0.01
Placebo pre vs. post (n = 18) No significant changes No significant changes N/A
1Significant metabolomic changes within treatment groups over time. For details of statistical analysis see Methods. AA, amino acid; BAIBA,
β-amino-isobutyric acid; HMB, β-hydroxy-β-methylbutyrate; MM, multiple micronutrient; NMND, N-methylnicotinamide; PAG, phenylacetylglutamine;
2-HIB, 2-hydroxyisobutyrate; 2-PY, N-methyl-2-pyridone-5-carboxamide; 3-IS, 3-indoxyl sulfate; 4-HH, 4-hydroxyhippurate.
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FIGURE 4 Associations between the urinary metabolic profile and MTORC1 (upper panels) or VH (lower panels) based on the OPLS models. The NMR
spectra are divided into 2 (right and left) to show the full range of δ1H. For each comparison the upper section of the panel shows the average 1H NMR spectrum
(intensity in arbitrary units) and the lower section shows a Manhattan plot which displays the −log10(P value) for each of the spectral variables. Statistically
significant peaks from the OPLS models are colored red if positively associated with MTORC1 or VH, and blue if inversely associated. n = 46 for both VH
and MTORC1 models. For details of statistical analysis see the Methods. 2-HIB, 2-hydroxyisobutyrate; 2-PY, N-methyl-2-pyridone-5-carboxamide; 4-CS,
4-cresyl sulfate; DMA, dimethylamine, DMG, dimethylglycine; GAA, guanidinoacetic acid; HMB, β-hydroxy-β-methylbutyrate; MTORC1, mechanistic (or
mammalian) target of rapamycin complex 1; PAG, phenylacetylglutamine; OPLS, orthogonal projection to latent structures; VH, villus height.
intestinal permeability and microbial translocation (9, 26). A
reduction in small bowel absorptive area over the course of the
rainy season (which coincided with the supplementation period)
was again observed. It is assumed that loss of absorptive capacity
is related to the increased pathogen load observed during the rainy
season, due to inadequate water and sanitation, but a reduction in
dietary quality and quantity and increased food prices during this
time may also be relevant, particularly with regards to nutrient-
sensing pathways. With hindsight, it would have been better to
have spread the trial over a full calendar year to include all
seasons.
Confocal endomicroscopy is a novel tool for evaluating
epithelial integrity in the intestinal mucosa (17, 32). We found
it to be highly reproducible when used to assess leak severity
measured by fluorescein efflux. There is evidence that fluorescein
leak is a reflection of disturbed tight junction proteins and
microerosions (17, 33). However, evaluation of details of
epithelial integrity at a cellular level is time-consuming, and
less reproducible than assessment of fluorescein leak. Although
we found a modest response of epithelial leak to AA + MM,
there was no response of a range of biomarkers of microbial
translocation to the interventions. It is possible that mucosal
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TABLE 7 Metabolomic changes correlated with postsupplementation VH and/or MTORC1 activity1
Outcome Positively correlated Negatively correlated P for model
VH (n = 46) HMB, DMG, creatine, creatinine, GAA, taurine, 2-PY, formate No significant changes 0.01
MTORC1 (n = 46) HMB, 2-HIB, 2-PY, pseudouridine, dimethylamine 4-CS, hippurate, PAG 0.01
1Differentially excreted urinary metabolites correlated with posttreatment VH and posttreatment MTORC1 responsiveness. For details of statistical
analysis see Methods. DMG, dimethylglycine; GAA, guanidinoacetic acid; HMB, β-hydroxy-β-methylbutyrate; MTORC1, mechanistic (or mammalian)
target of rapamycin complex 1; PAG, phenylacetylglutamine; VH, villus height; 2-HIB, 2-hydroxyisobutyrate; 2-PY, N-methyl-2-pyridone-5-carboxamide;
4-CS, 4-cresyl sulfate.
barrier function and epithelial integrity are regulated by different
factors to VH and villus surface area.
The lack of effect of HIV on mucosal morphometry and
on barrier function may seem surprising. However, the data
presented here are entirely consistent with our earlier work (9)
which showed that only in advanced AIDS did VH fall below
the range consistent with EE, whereas crypt depth was increased
earlier in HIV infection. We believe that in industrialized
countries HIV may affect villus morphology, but that in low- and
middle-income countries any such subtle effect is undetectable
alongside the EE, which is virtually ubiquitous.
Metabolomic analysis revealed a number of insights which
may merit further investigation. A number of host- and gut
microbial–derived metabolites were significantly correlated with
VH and/or CD4+ T lymphocyte MTORC1 responses. For
example, HMB was positively correlated with both MTORC1
and VH. HMB is a physiological leucine metabolite which has
been demonstrated to enhance lean muscle mass and strength
and decrease muscle protein breakdown via MTORC1 signaling
(34). Interestingly, HMB increased with the MM supplement but
not the leucine-containing AA supplement, suggesting that such
changes were not driven by increased leucine intake. HMB has
been previously observed to increase after zinc supplementation
in children from Brazil (unpublished data). The gut microbial–
host cometabolites 4-cresyl sulfate, PAG, and hippurate were all
negatively associated with MTORC1. These metabolites have
been found to be excreted in greater amounts by stunted children
and are thought to arise from an overgrowth of bacteria and
malabsorption in the small intestine preventing their precursors
from being absorbed, thus increasing their bioavailability for
microbial processing (35). Further work is required to assess their
direct potential to activate MTORC1.
The nicotinamide/NAD+ pathway has been previously ob-
served to be perturbed with chronic undernutrition and EE
(14, 15). NAD+ is key for many metabolic processes in-
cluding energy generation but is also important for DNA
repair processes. NAD+ can be synthesized from the dietary
precursors nicotinic acid (Preiss-Handler pathway), nicotinamide
and nicotinamide riboside (salvage pathway), or via tryptophan
(de novo biosynthesis pathway). Of note, either tryptophan
or nicotinic acid was supplemented in 3 of the 4 trial arms.
N-methylnicotinamide (NMND), a urinary marker of NAD+
abundance, has been positively associated with catch-up growth,
whereas N-methylnicotinic acid (NMNA; trigonelline) excretion
has been found to be reduced in wasted and underweight children.
NMNA is a dietary constituent found in legumes and coffee.
Although nicotinic acid is not methylated to NMNA in vivo, 1
study observed that when niacin-deficient rats received bound
nicotinic acid (niacytin) from cereals, a prolonged excretion
of NMNA followed. A defect in small intestinal permeability
was implicated in the mechanism. In the present study, MM
supplementation [containing nicotinic acid (niacin)] increased
the excretion of NMND and its breakdown product 2-PY and
decreased the excretion of NMNA. In addition, 2-PY was
positively associated with VH and MTORC1 activation.
The tryptophan–indoleamine 2,3-dioxygenase (IDO)–
kyneurine immunometabolic axis is currently a subject of
great interest. Tryptophan is partly metabolized through host
IDO 1 and 2 to produce kynurenines, and this pathway may be
subverted by microbial tryptophan uptake and metabolism. High
levels of IDO activity promote regulatory immune responses and
Treg differentiation and inhibit Teff differentiation (36, 37). In
stunted children with EE, plasma tryptophan concentrations are
correlated with growth (38), and the kynurenine to tryptophan
ratio (KTR, with high ratios indicative of high IDO activity) is
correlated with systemic markers of inflammation and inversely
correlated to growth (i.e., high KTR and presumed greater IDO
activity are associated with greater stunting) (30), suggesting that
microbial manipulation of tryptophan signaling and inhibition of
kynurenine production may be relevant in the pathophysiology
of EE. The metabolic differences observed in this study also
suggest a possible role for tryptophan signaling in modulating
the villus compartment and immune cell nutrient sensing.
A number of other metabolites correlated with VH, MTORC1
activity, or the interventions were identified. These can be broadly
classed as AA–derived (e.g., taurine, 4-cresyl sulfate, PAG),
tricarboxylic cycle intermediaries (e.g., succinate, formate), or
microbial coproducts (e.g., pseudouridine, hippurate). Although
some of these have been identified in undernourished/stunted
populations previously, the significance of these findings in this
study is unclear.
In recent reviews, it has been proposed that measurement of
EE should be considered in several domains—villus morphology,
permeability, microbial translocation, mucosal inflammation,
systemic inflammation, malabsorption, and changes in the
intestinal microbiota (35). Our data suggest that therapies for
EE may have a preferential impact on 1 of these domains (villus
morphology) without necessarily having a significant impact on
the others. Indeed, our previous work has suggested that the
observed villous atrophy may in fact have a protective role in
EE (17). This suggests that VH, itself determined by enterocyte
replication, migration, and apoptosis as well as stromal cells,
might be rate-limited by the availability of nutrients such as
glutamine, leucine, and tryptophan.
In summary, a safe and well-tolerated AA supplement in adults
with EE resulted in increased VH (i.e., changes in gut mucosal
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structure), but these changes were not matched by improvements
in intestinal barrier function, and intestinal barrier function only
improved in the AA+MMgroup. There was consistent evidence
of a correlation between VH and MTORC1 responsiveness in
lymphocytes. Further work is required to determine whether
modest improvements in small intestinal structure have relevant
physiological benefits, such as improved absorption of nutrients.
Given the promising effects of leucine in improving muscle mass
in other contexts (39), work on AA/MM supplementation could
provide benefits in >1 physiological system.
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